Two Sigma Investments, LP Lineage Cell Therapeutics, Inc. Transaction History
Two Sigma Investments, LP
- $42.8 Billion
- Q1 2025
A detailed history of Two Sigma Investments, LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 480,423 shares of LCTX stock, worth $514,052. This represents 0.0% of its overall portfolio holdings.
Number of Shares
480,423
Previous 301,544
59.32%
Holding current value
$514,052
Previous $150,000
44.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding LCTX
# of Institutions
140Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$53 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$10.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$9.54 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$7.26 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$6.04 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $182M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...